Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.69 USD

105.69
732,264

-0.76 (-0.71%)

Updated Nov 11, 2024 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Novartis (NVS) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Novartis (NVS) stood at $101, denoting a +0.03% change from the preceding trading day.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.

Novartis (NVS) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.

The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours

by Zacks Equity Research

Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.

Novartis (NVS) Stock Moves -1.17%: What You Should Know

by Zacks Equity Research

Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka

by Zacks Equity Research

Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.

Novartis (NVS) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

by Kinjel Shah

AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.

Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

by Kinjel Shah

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.

Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ekta Bagri headshot

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

by Ekta Bagri

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy

by Zacks Equity Research

Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.

Kinjel Shah headshot

3 Large Drug Stocks That Have Outperformed Industry YTD

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why

by Zacks Equity Research

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

by Zacks Equity Research

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals

by Zacks Equity Research

Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Procter & Gamble, Novartis & Mondelez International

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novartis AG (NVS) and Mondelez International, Inc. (MDLZ).

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

by Zacks Equity Research

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates

by Zacks Equity Research

Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.

Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY

by Zacks Equity Research

Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.